Core Viewpoint - The stock of Lai Kai Pharmaceutical-B (02105) rose nearly 5% in the afternoon, currently up 3.04% at HKD 13.88, with a trading volume of HKD 19.9183 million. The company announced that its new drug LAE118, aimed at treating PIK3CA-mutated solid tumors, has received acceptance for clinical trial application by the FDA [1]. Group 1 - Lai Kai Pharmaceutical's LAE118 is a novel PI3Kα pan-mutant selective inhibitor designed for PIK3CA mutated solid tumors [1]. - The company plans to work closely with regulatory authorities to complete the relevant application process [1]. - The company aims to provide this precision therapy to cancer patients in need of new treatment options, leveraging its proven track record in clinical development and licensing of LAE002 (afuresertib) [1].
来凯医药-B午后涨近5% 美国FDA受理LAE118新药临床试验申请